Embrace the complexity of global healthcare

WALTHAM, Mass., September 23, 2021 / PRNewswire / – Fresenius Medical Care, the world’s leading provider of products and services for people with kidney disease, has announced the release of its 2021 Global Annual Medical Report. Entitled “Embracing the Complexity of Global Healthcare,” the report focuses on solving the complexity of healthcare by driving meaningful advancements in kidney disease care.

“The volume of thought leadership, insights and expertise in the report demonstrates our company’s continued leadership in kidney care, our innovation through lifelong learning, and our commitment to our focused mission. on the patient, ”said Franklin W. Maddux, MD, Global Chief Medical Officer of Fresenius Medical Care.

The 2021 Global Annual Medical Report includes 25 chapters written by more than 40 authors from across the company. Six different sections each focus on a central theme of the clinical and quality program of Fresenius Medical Care. An additional COVID-19 section is dedicated to the company’s ongoing efforts to deal with the pandemic.

The central themes are:

  • Cardiovascular health
  • Precision medicine
  • Communication and medical education
  • Global search
  • Patient-centered care
  • Innovation and transformation

The 2021 Global Annual Medical Report is published by the Global Medical Office of Fresenius Medical Care. The full report is now available online at: https://fmcna.com/insights/amr/

Fresenius Medical Care is the world’s leading provider of products and services for people with kidney disease, with approximately 3.7 million patients worldwide undergoing regular dialysis treatment. Through its network of more than 4,100 dialysis clinics, Fresenius Medical Care provides dialysis treatment to approximately 346,000 patients worldwide. Fresenius Medical Care is also the leading supplier of dialysis products such as dialysis machines or dialyzers. Along with its core business, the Renal Care Continuum, the company is focusing on its expansion in complementary areas and in the field of intensive care. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and the New York Stock Exchange (FMS).

For more information, visit the company’s website at www.freseniusmedicalcare.com.

This press release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts linked to the results of the COVID-19 pandemic. clinical studies, fluctuations in exchange rates, uncertainties in litigation or investigative procedures and the availability of funding. These and other risks and uncertainties are detailed in the reports of Fresenius Medical Care AG & Co. KGaA filed with the United States Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA assumes no responsibility for updating any forward-looking statements contained in this press release.

Media contact
Michel gavin
T +49 6172 609-2978
[email protected]

Media contact for North America
Brad puffer
T +1 781-699-3331
[email protected]

Contact for analysts and investors
Dr. Dominique heger
T +49 6172 609-2601
[email protected]


SOURCE Fresenius Medical Care Holdings, Inc.

Related links